
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
GENERAL COMMENTARY article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1575090
This article is part of the Research Topic The Tumor Microenvironment and Immunotherapy for Head and Neck Tumors View all 16 articles
This article is a commentary on:
Disulfidptosis-Related Gene Signatures as Prognostic Biomarkers and Predictors of Immunotherapy Response in HNSCC
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Analysis"-they believed that in high-risk HNSCC, the sensitivity of belinostat, SB52334, and CAL-29 101 was significantly higher than in the low-risk group, while Dasatinib, Pazopanib, and Docetaxel 30 showed higher sensitivity in low-risk HNSCC (1). 31 IC50, defined as the half maximal inhibitory concentration, signifies the concentration at which a 32 drug or inhibitor diminishes the activity of a biological process (such as an enzyme, receptor, or cell) 33 to half of its maximum level under specific experimental conditions. A lower IC50 value indicates 34 that the drug can achieve a 50% inhibitory effect at a lower concentration, suggesting a higher potency and sensitivity of the drug (2,3). Therefore, the correct interpretation of Figure 11B
Keywords: Half maximal inhibitory concentration (IC50), medication, disulfidptosis-related genes (DRGs), Head and neck squamous cell carcinoma (HNSCC), Immunotherapy
Received: 11 Feb 2025; Accepted: 04 Mar 2025.
Copyright: © 2025 Xue, Xue, Yin, Chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ming Wang, Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.